Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study

被引：0
|
作者：
Awad, M. [1 ]
Le Bruchec, Y. [2 ]
Markelewicz, R. [3 ]
Chen, P. [3 ]
Fandi, A. [3 ]
Spira, A. [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Celgene Int, Boudry, Switzerland
[3] Celgene Corp, Summit, NJ USA
[4] Virginia Canc Specialists, Fairfax, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
ACY-241; Nivolumab; NSCLC;
D O I：
10.1016/j.jtho.2017.09.453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 02.03
引用
收藏
页码：S1804 / S1804
页数：1
相关论文
共 50 条
  • [1] Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
    Awad, Mark M.
    Le Bruchec, Yvan
    Lu, Brian
    Ye, Jason
    Miller, JulieAnn
    Lizotte, Patrick H.
    Cavanaugh, Megan E.
    Rode, Amanda J.
    Dumitru, Calin Dan
    Spira, Alexander
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study (vol 11, 696512, 2021)
    Awad, Mark M.
    Le Bruchec, Yvan
    Lu, Brian
    Ye, Jason
    Miller, Julie Ann
    Lizotte, Patrick H.
    Cavanaugh, Megan E.
    Rode, Amanda J.
    Dumitru, Calin Dan
    Spira, Alexander
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241+nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).
    Awad, Mark M.
    Le Bruchec, Yvan
    Lu, Brian
    Miller, Julieann
    Dumitru, Calin Dan
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with ALK plus NSCLC
    Shaw, Alice
    Loong, Herbert
    Tan, Daniel S. -W.
    Griscti, Kerry
    Gao, Haitao
    Finckenstein, Friedrich
    Scott, Jeffrey
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S430 - S430
  • [5] Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma
    Weber, Jeffrey S.
    Levinson, Benjamin A.
    Laino, Andressa S.
    Pavlick, Anna C.
    Woods, David M.
    MELANOMA RESEARCH, 2022, 32 (05) : 324 - 333
  • [6] A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).
    Gordon, Michael S.
    Shapiro, Geoffrey
    Sarantopoulos, John
    Juric, Dejan
    Lu, Brian
    Chen, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] ACY-241, a histone deacetylase 6 inhibitor, suppresses the epithelial-mesenchymal transition in lung cancer cells by downregulating hypoxia-inducible factor-1 alpha
    Park, Seong-Jun
    Lee, Naeun
    Jeong, Chul-Ho
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2024, 28 (01): : 83 - 91
  • [8] A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Heist, Rebecca
    Vokes, Everett
    Angevin, Eric
    Hong, David S.
    Rybkin, Igor I.
    Barve, Minal
    Bauer, Todd M.
    Delmonte, Angelo
    Dunbar, Martin
    Motwani, Monica
    Parikh, Apurvasena
    Noon, Elysa
    Wu, Jun
    Blot, Vincent
    Kelly, Karen
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
  • [9] Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC
    Konduri, K.
    Spira, A. I.
    Jotte, R. M.
    Boyd, T.
    Boyd, T.
    Gaffar, Y. A.
    Reynolds, C.
    Witta, S. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study
    Neal, Joel W.
    Santoro, Armando
    Gonzalez-Cao, Maria
    Lim, Farah Louise
    Fang, Bruno
    Gentzler, Ryan D.
    Goldschmidt, Jerome
    Khrizman, Polina
    Proto, Claudia
    Patel, Shiven
    Puri, Sonam
    V. Liu, Stephen
    Massarelli, Erminia
    Williamson, Denise
    Schwickart, Martin
    Scheffold, Christian
    Andrianova, Svetlana
    Felip, Enriqueta
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (10):
12345